MOTS-c Dosage and Side Effects: What Studies Actually Used — Not a Recommendation

"MOTS-c dosage" and "MOTS-c side effects" together get searched roughly 3,700 times a month, and most of what answers either query hands back a specific injection amount and a short, reassuring safety list. Neither exists in the published record. As our evidence review covers in full, MOTS-c has never been dosed into a human being as the native, 16-amino-acid peptide in any completed clinical trial — the only human interventional drug trial in this entire discovery lineage tested CB4211, a different company's engineered analog, for a different condition. That gap shapes both halves of this article. What follows is not a dosing chart or an adverse-event list reformatted from a label that doesn't exist — it's exactly what the published mouse studies and the CB4211 trial record actually disclose, including the specific gaps in what they disclose, reported precisely rather than filled in by inference.

What the animal dosing record actually shows — and a gap worth naming directly

Here is the detail that sets MOTS-c apart from every other peptide this site has reviewed in this format, BPC-157 included: even the foundational mouse studies behind MOTS-c's own discovery do not state their dose in the published abstract.

• •The 2015 discovery paper. The study that first identified MOTS-c and reported it "prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity" in mice does not disclose, anywhere in its own published abstract, the milligram-per-kilogram dose used, the injection route, or the dosing frequency¹. Our BPC-157 dosage article found the same kind of gap in one or two individual studies out of five; for MOTS-c, this gap appears in the very first paper anyone would look to for a dose figure.
• •The 2021 healthspan study. A follow-up study from the same research lineage reports its treatment schedule with real precision for one specific cohort — mice that began "late-life (23.5 mo.) initiated intermittent MOTS-c treatment," dosed "3x/week"² — but, like the 2015 paper, never states the per-dose amount or the injection route anywhere in its own abstract text.

Put plainly: this review can report that one late-life mouse cohort in the published literature received MOTS-c three times a week, and that's the single most specific animal-dosing detail located in either paper's own abstract. Neither paper's abstract discloses how much was in each of those three weekly doses, or by what route. A reader would need the full methods section of each paper — not indexed in what this review's live PubMed searches returned — to find that number, and this article is not willing to guess at it or borrow a figure from a vendor page that doesn't cite its own source.

Why there's no MOTS-c dosing chart on this page

The same reasoning our BPC-157 dosage article applies to a much thinner underlying record: a real dosing chart would require converting a mouse study's dose into a human one by a validated method, and that starts from having the mouse dose in the first place — which, as the section above shows, this review could not locate in either foundational paper's own published abstract. Layered on top of that missing animal number is the same fact our evidence review covers in depth: the one completed human interventional trial in this discovery lineage dosed CB4211, CohBar's own engineered analog, not native-sequence MOTS-c — so even a reader willing to accept an animal-to-human extrapolation has no human trial of the actual molecule to extrapolate toward. Our MOTS-c reconstitution calculator will do the vial-to-syringe arithmetic on a number you already have from somewhere else — pure math on whatever you enter, with no claim that the number itself is validated, appropriate, or legal.

What CB4211's trial record does — and doesn't — establish about dosing

CB4211's Phase 1a/1b trial (NCT03998514, sponsor CohBar, Inc.) is worth walking through structurally, because its own dosing design shows how far even a company running a real, sponsored, FDA-cleared study got — and it still isn't a MOTS-c number. The trial ran in three parts: a single-ascending-dose arm in healthy non-obese volunteers, testing six sequential dose-level cohorts as one-time subcutaneous injections into the abdomen (or thigh, if needed); a multiple-ascending-dose arm, three cohorts dosed once daily subcutaneously for 7 days; and a third arm in people with nonalcoholic fatty liver disease, dosed once daily subcutaneously for 28 days. The registry's own record never states the actual milligram or milligram-per-kilogram dose for any of those cohorts — every level is referenced only by a sequential code (A1 through A6, B1 through B3), and the NAFLD arm's own dose field reads "to be determined (TBD)."

That structure is itself informative, independent of any specific number: it's what a real dose-finding study looks like — start low, escalate cohort by cohort under safety monitoring, let the data (not a preset chart) decide the next dose. It is also, again, CB4211's structure and CB4211's (undisclosed) doses, not MOTS-c's.

What the safety record actually shows

No adverse-effect signal has been reported in the published animal literature — but that's a narrower claim than it sounds, for the same reason it is in BPC-157's case: these were efficacy studies (insulin resistance, physical performance, bone metabolism), not dedicated toxicology programs, and none of the papers this review located reports a MOTS-c-specific adverse finding one way or the other. Absence of a reported problem in an efficacy study is not the same evidentiary weight as a clean result from a study built to look for one.

CB4211's own safety data has never been made public. This is the most direct, checkable finding in this entire dosage/side-effects review: NCT03998514 completed on April 19, 2021, and a live re-check of its own ClinicalTrials.gov record confirms its own "hasResults" field still reads false — more than five years after completion, no results section, including any adverse-event summary, has ever been posted to the registry for this trial. That means the one human interventional trial that dosed any MOTS-c-family compound into a living person has no public safety outcome attached to it at all, not even an unpublished-but-registered summary table. This article treats that as a real, current, checkable gap rather than assuming a completed-but-unpublished trial was clean.

The regulatory record is itself a safety-relevant signal, and a comparatively cautious one. MOTS-c sat in FDA's interim 503A Category 2 (significant safety risk) bulk-substances list from 2023 until its removal on April 15, 2026, via nominator withdrawal — a procedural change, not an FDA safety reversal³. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee reviewed MOTS-c for the uses "Obesity and osteoporosis" and voted to recommend it for the 503A Bulks List by the narrowest margin of any peptide reviewed that day — 7 in favor, 5 against, 2 abstentions, versus the identical 8-6-1 tally BPC-157, TB-500, and KPV each received at the same two-day meeting³. A narrower advisory-committee vote is not a rejection, and it is not proof of danger — but it is a comparative signal worth reporting plainly: MOTS-c's own evidence base, thinner and less human-tested than its peptide-market neighbors' by every measure in this article and its companion evidence review, produced the least confident recommendation among them.

Contamination and manufacturing-quality risk is a separate, real category this article's safety data says nothing about. As with every unapproved compounded peptide this site has reviewed, no dosing or safety finding above — animal or CB4211 human data alike — tells a reader anything about the purity, actual peptide content, or sterility of a specific vial purchased from an unregulated seller.

The bottom line

Two gaps, stacked on top of each other, are the real story here. The animal literature behind MOTS-c's discovery and its healthspan claims doesn't state its own dose in either foundational paper's published abstract — a more severe transparency gap than this site has found in any other peptide's animal record, including BPC-157's. And the one completed human interventional trial in this molecule's discovery lineage tested a different company's different, engineered analog, for a different condition, with its own safety results never made public more than five years after the trial completed. There is no validated MOTS-c dose this site, or any other legitimate source, can respectably hand you, and no completed human safety trial of the actual molecule to report on. Our MOTS-c evidence review covers the full picture, including why endogenous, exercise-induced MOTS-c levels measured in several real human studies are a genuinely different category of evidence from a drug trial. For the same regulatory review cycle applied to MOTS-c's peptide-market neighbors, see our KPV dosage article, our TB-500 dosage and side effects review, and our BPC-157 dosage and side-effects articles.